Therapeutic strategies for the management of gliomas;Stratégies thérapeutiques pour le traitement des gliomes

Revue Neurologique

Volumn 164, Issue 6-7, 2008, Pages 523-530

  Hottinger, A F ^a   Stupp, R ^b  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Astrocytoma; Chemotherapy; Glioblastoma; Glioma; Oligodendroglioma; Review

Indexed keywords

BEVACIZUMAB; ERLOTINIB; IRINOTECAN; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; TEMOZOLOMIDE;

ASTROCYTOMA; CANCER SURVIVAL; CHROMOSOME 19Q; CHROMOSOME 1P; CHROMOSOME TRANSLOCATION 1; CHROMOSOME TRANSLOCATION 19; GLIOBLASTOMA; GLIOMA; HUMAN; MEDICAL SPECIALIST; OLIGODENDROGLIOMA; PROGNOSIS; REVIEW; SURGEON;

ANTINEOPLASTIC AGENTS, ALKYLATING; ASTROCYTOMA; BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; DACARBAZINE; GLIOBLASTOMA; GLIOMA; HUMANS; NEOPLASM RECURRENCE, LOCAL; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE; OLIGODENDROGLIOMA;

EID: 46149099169     PISSN: 00353787     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neurol.2008.03.012     Document Type: Review

References (52)

1. Brada M., Judson I., Beale P., et al. Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies. Br J Cancer 81 (1999) 1022-1030
2. Brandes AA, Franceschi E, Tosoni A, et al. (2008). MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomittant radiochemotherapy in newly diagnosed glioblastoma patients. JCO, in print
3. Brandes A.A., Stupp R., Hau P., et al. EORTC study 26041-22041: phase I/II study on concomittant and adjuvant temozolomide and radiotherapy with or without PTK787/ZK222584 in newly diagnosed glioblastoma. JCO 25 (2007) 2026
4. Brandes A.A., Tosoni A., Cavallo G., et al. Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO). Br J Cancer 95 (2006) 1155-1160
5. Brandes A.A., Tosoni A., Vastola F., et al. Efficacy and feasibility of standard procarbazine, lomustine, and vincristine chemotherapy in anaplastic oligodendroglioma and oligoastrocytoma recurrent after radiotherapy. A phase II study. Cancer 101 (2004) 2079-2085
6. Burger P.C. What is an oligodendroglioma?. Brain Pathol 12 (2002) 257-259
7. Cairncross G., Berkey B., Shaw E., et al. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: intergroup radiation therapy oncology group trial 9402. J Clin Oncol 24 (2006) 2707-2714
8. Cairncross J.G., and MacDonald D.R. Successful chemotherapy for recurrent malignant oligodendroglioma. Ann Neurol 23 (1988) 360-364
9. Chamberlain M.C. Salvage chemotherapy with CPT-11 for recurrent glioblastoma multiforme. J Neurooncol 56 (2002) 183-188
10. Chamberlain M.C., Glantz M.J., Chalmers L., Van Horn A., and Sloan A.E. Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma. J Neurooncol 82 (2007) 81-83
11. Cloughesy T, Prados M, Wen P, et al. (2007). A phase II, randomized, non-comparative clinical trial of bevacizumab alone or in combination with CPT-11 prolongs 6-month PFS in recurrent, treatment-refractory glioblastoma. 12th annual SNO meeting, Dallas, Texas.
12. Cloughesy T.F., Filka E., Kuhn J., et al. Two studies evaluating irinotecan treatment for recurrent malignant glioma using an every-3-week regimen. Cancer 97 (2003) 2381-2386
13. Davis F.G., McCarthy B.J., Freels S., Kupelian V., and Bondy M.L. The conditional probability of survival of patients with primary malignant brain tumors: surveillance, epidemiology, and end results (SEER) data. Cancer 85 (1999) 485-491
14. de Wit M.C., de Bruin H.G., Eijkenboom W., Sillevis Smitt P.A., and van den Bent M.J. Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression. Neurology 63 (2004) 535-537
15. DeAngelis L.M. Brain tumors. N Engl J Med. 344 (2001) 114-123
16. Dresemann G. (2007). Imatinib plus hydroxyurea versus hydroxyurea monotherapy in progressive glioblastoma (GBM), an international multi-center, open label, randomised, phase III study (AMBROSIA-Study, STI571BDE40). 12th annual SNO Meeting, Dallas, Texas.
17. Franceschi E., Omuro A.M., Lassman A.B., Demopoulos A., Nolan C., and Abrey L.E. Salvage temozolomide for prior temozolomide responders. Cancer 104 (2005) 2473-2476
18. Gerber D.E., Grossman S.A., Zeltzman M., Parisi M.A., and Kleinberg L. The impact of thrombocytopenia from temozolomide and radiation in newly diagnosed adults with high-grade gliomas. Neuro-oncol 9 (2007) 47-52
19. Hare C.B., Elion G.B., Houghton P.J., et al. Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against pediatric and adult central nervous system tumor xenografts. Cancer Chemother Pharmacol 39 (1997) 187-191
20. Hegi M.E., Diserens A.C., Gorlia T., et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352 (2005) 997-1003
21. Hildebrand J., De Witte O., and Sahmoud T. Response of recurrent glioblastoma and anaplastic astrocytoma to dibromodulcitol, BCNU and procarbazine-a phase-II study. J Neurooncol 37 (1998) 155-160
22. Karim A.B., Afra D., Cornu P., et al. Randomized trial on the efficacy of radiotherapy for cerebral low-grade glioma in the adult: European organization for research and treatment of cancer study 22845 with the medical research council study BRO4: an interim analysis. Int J Radiat Oncol Biol Phys 52 (2002) 316-324
23. Keime-Guibert F., Chinot O., Taillandier L., et al. Radiotherapy for glioblastoma in the elderly. N Engl J Med 356 (2007) 1527-1535
24. Khan R.B., Raizer J.J., Malkin M.G., Bazylewicz K.A., and Abrey L.E. A phase II study of extended low-dose temozolomide in recurrent malignant gliomas. Neuro-oncol 4 (2002) 39-43
25. Kros J.M. From expert opinion to evidence-based: changes in the gold standard of primary brain tumour diagnosis. J Pathol 213 (2007) 1-3
26. Louis D.N., Ohgaki H., Wiestler O.D., and Cavenee W.K.E. WHO classification of tumours of the central nervous system. 3rd ed. (2007), IARC, Lyon, France
27. MacDonald D.R., Gaspar L.E., and Cairncross J.G. Successful chemotherapy for newly diagnosed aggressive oligodendroglioma. Ann Neurol 27 (1990) 573-574
28. Mirimanoff R., and Stupp R. Long-terms survival in glioblastoma possible? Updated results of the EORTC/NCIC Phase III randomized trial on radiotherapy (RT) and concomitant and adjuvant temozolomide (TMZ) versus RT Alone. Int J Radiat Oncol Biol Phys 69 Suppl. S (2007) S2
29. Mutter N., and Stupp R. Temozolomide: a milestone in neuro-oncology and beyond?. Expert Rev Anticancer Ther 6 (2006) 1187-1204
30. Ostermann S., Csajka C., Buclin T., et al. Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients. Clin Cancer Res 10 (2004) 3728-3736
31. Pignatti F., Van den Bent M., Curran D., et al. Prognostic factors for survival in adult patients with cerebral low-grade glioma. J Clin Oncol 20 (2002) 2076-2084
32. Prados M.D., Lamborn K., Yung W.K., et al. A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study. Neuro-oncol 8 (2006) 189-193
33. Reardon D.A., Egorin M.J., Quinn J.A., et al. Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme. J Clin Oncol 23 (2005) 9359-9368
34. Roa W., Brasher P.M., Bauman G., et al. Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial. J Clin Oncol 22 (2004) 1583-1588
35. Sanson M., Cartalat-Carel S., Taillibert S., et al. Initial chemotherapy in gliomatosis cerebri. Neurology 63 (2004) 270-275
36. Scott C.B., Scarantino C., Urtasun R., et al. Validation and predictive power of radiation therapy oncology group (RTOG) recursive partitioning analysis classes for malignant glioma patients: a report using RTOG 90-06. Int J Radiat Oncol Biol Phys 40 (1998) 51-55
37. Seiwert T.Y., Salama J.K., and Vokes E.E. The concurrent chemoradiation paradigm-general principles. Nat Clin Pract Oncol 4 (2007) 86-100
38. Shaw E., Arusell R., Scheithauer B., et al. Prospective randomized trial of low- versus high-dose radiation therapy in adults with supratentorial low-grade glioma: initial report of a north central cancer treatment group/radiation therapy oncology group/eastern cooperative oncology group study. J Clin Oncol 20 (2002) 2267-2276
39. Stupp R., Dietrich P.Y., Ostermann Kraljevic S., et al. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol 20 (2002) 1375-1382
40. Stupp R., Gander M., Leyvraz S., and Newlands E. Current and future developments in the use of temozolomide for the treatment of brain tumours. Lancet Oncol 2 (2001) 552-560
41. Stupp R., Hegi M.E., Gilbert M.R., and Chakravarti A. Chemoradiotherapy in malignant glioma: standard of care and future directions. J Clin Oncol 25 (2007) 4127-4136
42. Stupp R., Hegi M.E., van den Bent M.J., et al. Changing paradigms-an update on the multidisciplinary management of malignant glioma. Oncologist 11 (2006) 165-180
43. Stupp R., Mason W.P., van den Bent M.J., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352 (2005) 987-996
44. Taliansky-Aronov A., Bokstein F., Lavon I., and Siegal T. Temozolomide treatment for newly diagnosed anaplastic oligodendrogliomas: a clinical efficacy trial. J Neurooncol 79 (2006) 153-157
45. Tolcher A.W., Gerson S.L., Denis L., et al. Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules. Br J Cancer 88 (2003) 1004-1011
46. Van den Bent M, Brandes AA, Rampling R, et al. (2007). Randomized phase II trial of erlotinib versus temozolomide or BCNU in recurrent glioblastoma multiforme: EORTC 26034. J Clin Oncol, 2007 ASCO Annual Meeting Proceedings Part I 2007; 25 (suppl): 76s (abstract 2004).
47. van den Bent M.J., Afra D., de Witte O., et al. Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet 366 (2005) 985-990
48. van den Bent M.J., Carpentier A.F., Brandes A.A., et al. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European organisation for research and treatment of cancer phase III trial. J Clin Oncol 24 (2006) 2715-2722
49. van den Bent M.J., Taphoorn M.J., Brandes A.A., et al. Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European organization for research and treatment of cancer, brain tumor group study 26971. J Clin Oncol 21 (2003) 2525-2528
50. Vredenburgh J.J., Desjardins A., Herndon J.E.N., et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 13 (2007) 1253-1259
51. Vredenburgh J.J., Desjardins A., Herndon J.E.N., et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 25 (2007) 4722-4729
52. Wick A., Felsberg J., Steinbach J.P., et al. Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma. J Clin Oncol 25 (2007) 3357-3361